血管紧张素Ⅱ治疗新型冠状病毒肺炎诱导的血管舒张性休克的生理学反应:回顾性匹配队列研究
本研究为回顾性连续样本队列研究,纳入纽约3个医疗ICU中因新型冠状病毒肺炎呼吸衰竭并接受去甲肾上腺素治疗的分布性休克患者,比较接受血管紧张素Ⅱ治疗≥1小时者(n=10)与按2:1层次匹配的对照(n=19)。尽管匹配后血管紧张素Ⅱ组基线血管升压药需求更高(平均0.489 vs 0.097 µg/kg/min)、氧合更差且酸中毒更重,血管紧张素Ⅱ治疗仍与去甲肾上腺素当量剂量即时和持续下降相关(6小时模型β=-0.036 µg/kg/min/hr,95%CI -0.054至-0.018,交互作用P=0.0002;7天模型β=-0.04 µg/kg/min/d,95%CI -0.05至-0.03,交互作用P=0.0002)。与对照相比,血管紧张素Ⅱ组平均动脉压、高碳酸血症、酸中毒、基线校正肌酐和D-二聚体改善更快。3例血栓事件均发生在对照组。作者结论认为血管紧张素Ⅱ在新型冠状病毒肺炎诱导的休克中值得进一步研究。
要点
- 在新型冠状病毒肺炎诱导的分布性休克中,血管紧张素Ⅱ治疗与去甲肾上腺素当量剂量即时和持续下降相关(6小时β=-0.036 µg/kg/min/hr,95%CI -0.054至-0.018,交互作用P=0.0002)。
- 匹配后血管紧张素Ⅱ组基线血管升压药需求更高(平均0.489 vs 0.097 µg/kg/min),仍观察到平均动脉压改善更快。
- 血管紧张素Ⅱ组高碳酸血症、酸中毒、基线校正肌酐和D-二聚体改善均显著快于对照组。
- 3例血栓事件全部发生在对照组,血管紧张素Ⅱ组未报告血栓事件。
- 作者结论认为血管紧张素Ⅱ在新型冠状病毒肺炎诱导的休克中值得进一步研究。
适用人群与场景
- 纳入:新型冠状病毒肺炎诱导的呼吸衰竭并接受去甲肾上腺素治疗的分布性休克成人ICU患者,来自纽约3个医疗ICU。
- 治疗组:接受血管紧张素Ⅱ治疗≥1小时者;时间零点为血管紧张素Ⅱ启动时间。
- 对照组:按2:1层次过程匹配(入院日期和单元、特定器官支持方式、年龄、慢性肺/心血管/肾脏疾病、性别),时间零点为血管升压药启动后21小时(治疗组启动血管紧张素Ⅱ前血管升压药治疗的平均时长)。
处置流程与药物剂量
- 治疗组接受血管紧张素Ⅱ治疗≥1小时,原文未报告具体剂量、给药途径、频次或疗程。
- 对照组接受标准治疗,包括去甲肾上腺素;原文未报告对照组具体方案。
研究设计与关键结果
- 研究类型:回顾性连续样本队列研究,3个医疗ICU,样本量29例(血管紧张素Ⅱ组n=10,对照组n=19)。
- 主要终点:血管升压药需求(去甲肾上腺素当量剂量)和平均动脉压轨迹。血管紧张素Ⅱ治疗与去甲肾上腺素当量剂量即时和持续下降相关:6小时模型β=-0.036 µg/kg/min/hr(95%CI -0.054至-0.018,交互作用P=0.0002);7天模型β=-0.04 µg/kg/min/d(95%CI -0.05至-0.03,交互作用P=0.0002)。
- 基线:尽管匹配,血管紧张素Ⅱ组血管升压药需求更高(平均0.489 vs 0.097 µg/kg/min),氧合障碍和酸中毒更重。
- 关键次要终点:与对照组相比,血管紧张素Ⅱ组平均动脉压、高碳酸血症、酸中毒、基线校正肌酐和D-二聚体改善显著更快。
- 不良事件:3例血栓事件,全部发生在对照组。
证据类型、等级与局限
- 证据类型:回顾性匹配队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为血管紧张素Ⅱ在新型冠状病毒肺炎诱导的分布性休克中值得进一步研究。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the early physiologic response to angiotensin-II treatment in patients with coronavirus disease 2019-induced respiratory failure and distributive shock.
DESIGN: Retrospective consecutive-sample cohort study.
SETTING: Three medical ICUs in New York during the coronavirus disease 2019 outbreak.
PATIENTS: All patients were admitted to the ICU with respiratory failure and were receiving norepinephrine for distributive shock.
INTERVENTIONS: The treatment groups were patients who received greater than or equal to 1 hour of angiotensin-II treatment. Time-zero was the time of angiotensin-II initiation. Controls were identified using a 2:1 hierarchical process that matched for 1) date and unit of admission; 2) specific organ support modalities; 3) age; 4) chronic lung, cardiovascular, and kidney disease; and 5) sex. Time-zero in the control group was 21 hours post vasopressor initiation, the mean duration of vasopressor therapy prior to angiotensin-II initiation in the treated group.
MEASUREMENTS AND MAIN RESULTS: Main outcomes were trajectories of vasopressor requirements (in norepinephrine-equivalent dose) and mean arterial pressure. Additionally assessed trajectories were respiratory (Pao2/Fio2, Paco2), metabolic (pH, creatinine), and coagulation (d-dimer) dysfunction indices after time-zero. We also recorded adverse events and clinical outcomes. Trajectories were analyzed using mixed-effects models for immediate (first 6 hr), early (48 hr), and sustained (7 d) responses. Twenty-nine patients (n = 10 treated, n = 19 control) were identified. Despite matching, angiotensin-II-treated patients had markedly greater vasopressor requirements (mean: 0.489 vs 0.097 µg/kg/min), oxygenation impairment, and acidosis at time-zero. Nonetheless, angiotensin-II treatment was associated with an immediate and sustained reduction in norepinephrine-equivalent dose (6 hr model: β = -0.036 µg/kg/min/hr; 95% CI: -0.054 to -0.018 µg/kg/min/hr, p interaction=0.0002) (7 d model: β = -0.04 µg/kg/min/d, 95% CI: -0.05 to -0.03 µg/kg/min/d; p interaction = 0.0002). Compared with controls, angiotensin-II-treated patients had significantly faster improvement in mean arterial pressure, hypercapnia, acidosis, baseline-corrected creatinine, and d-dimer. Three thrombotic events occurred, all in control patients.
CONCLUSIONS: Angiotensin-II treatment for coronavirus disease 2019-induced distributive shock was associated with rapid improvement in multiple physiologic indices. Angiotensin-II in coronavirus disease 2019-induced shock warrants further study.
参考来源
- Leisman DE, Mastroianni F, Fisler G, et al. Physiologic Response to Angiotensin II Treatment for Coronavirus Disease 2019-Induced Vasodilatory Shock: A Retrospective Matched Cohort Study. Crit Care Explor. 2020. PMID: 33063034. doi:10.1097/CCE.0000000000000230
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。